ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 50,000 Shares

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Jaume Pons sold 50,000 shares of the business’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $14.20, for a total transaction of $710,000.00. Following the completion of the transaction, the insider now directly owns 604,205 shares of the company’s stock, valued at $8,579,711. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jaume Pons also recently made the following trade(s):

• On Thursday, April 4th, Jaume Pons sold 20,000 shares of ALX Oncology stock. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00.

ALX Oncology Price Performance

ALXO opened at $15.74 on Friday. The company has a fifty day moving average price of $13.55 and a two-hundred day moving average price of $11.90. The firm has a market capitalization of $789.36 million, a PE ratio of -4.20 and a beta of 1.58. ALX Oncology Holdings Inc. has a 52 week low of $3.94 and a 52 week high of $17.42. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.24 and a current ratio of 5.24.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). As a group, analysts anticipate that ALX Oncology Holdings Inc. will post -3.33 earnings per share for the current year.

Hedge Funds Weigh In On ALX Oncology

Institutional investors have recently modified their holdings of the stock. FMR LLC boosted its stake in ALX Oncology by 0.3% during the 1st quarter. FMR LLC now owns 6,129,441 shares of the company’s stock worth $27,705,000 after acquiring an additional 16,013 shares during the last quarter. State Street Corp grew its holdings in shares of ALX Oncology by 47.9% in the 1st quarter. State Street Corp now owns 2,133,744 shares of the company’s stock valued at $36,060,000 after buying an additional 691,410 shares during the period. BlackRock Inc. raised its stake in ALX Oncology by 7.2% during the 2nd quarter. BlackRock Inc. now owns 1,788,760 shares of the company’s stock worth $13,434,000 after buying an additional 120,136 shares during the period. Vestal Point Capital LP bought a new position in ALX Oncology during the fourth quarter worth about $24,643,000. Finally, Vanguard Group Inc. grew its stake in ALX Oncology by 49.0% in the fourth quarter. Vanguard Group Inc. now owns 1,502,409 shares of the company’s stock valued at $22,371,000 after acquiring an additional 494,173 shares during the period. 97.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ALXO. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a report on Friday, April 12th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of ALX Oncology in a research note on Wednesday, April 10th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $14.00 price target (up previously from $10.00) on shares of ALX Oncology in a report on Friday, March 8th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.83.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.